bearish
Aurobindo Pharma (ARBP IN): Pain Continues in the U.S. Formulation Business
303 Views03 Mar 2022 23:40
SUMMARY
- Aurobindo Pharma (ARBP IN) shares have corrected more than 40% from peak and are trading at discount to peers. The company’s U.S. business is under pressure, resulting in deteriorating profitability.
- We are not seeing any immediate respite in the U.S. formulation business. Hence, investors can avoid Aurobindo Pharma shares.
- However, value unlocking through stake sale in injectable business can be a near-term catalyst, resulting in relief rally in the stock.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Aurobindo Pharma (ARBP IN): Q3 Net Profit Dropped; R&D Cost To Remain Elevated in Near-Term02 Mar 2023
- Aurobindo Pharma (ARBP IN): Regulatory Issues Continue to Haunt the Company15 May 2022
- Aurobindo Pharma (ARBP IN): Pain Continues in the U.S. Formulation Business03 Mar 2022
x